Calling off-label repurposing of established drugs "under explored" is a bit insulting to all those people that attempt it all the time, without a higher success rate than any other method. Folks like Razelle Kuzrock make great progress, and the "under exploration" is more about not spending enough time exploring RNA or protein diagnostics rather than DNA diagnostics, if anything. Which isn't due to lack of impact or profit optimization, just due to intuition biases of the field.
Calling profit and impact optimization "uncorrelated" is not justified by your comment. The biggest impact in the past decade of cancer has undoubtedly been immunotherapies, which are also by far hugely profitable. And immunotherapies themselves were often a backwater, far more so than drug repurposing, until the impact came through with a patented drug.
Calling profit and impact optimization "uncorrelated" is not justified by your comment. The biggest impact in the past decade of cancer has undoubtedly been immunotherapies, which are also by far hugely profitable. And immunotherapies themselves were often a backwater, far more so than drug repurposing, until the impact came through with a patented drug.